Agoracom Blog Home

Archive for the ‘ORTHO Regenerative Technologies’ Category

VIDEO – ORTHO Regenerative Technologies $ORTH.ca $ORTIF Is Preparing for The Big League, Appointing Patrick O’Donnell to Help Bring its Proprietary Surgery Tech to NASDAQ

Posted by AGORACOM-JC at 4:17 PM on Monday, March 1st, 2021
Ortho

Last week we introduced you to ORTHO Regenerative Technologies, a cutting-edge med tech firm that uses its proprietary RESTORE technology platform to dramatically improve the success rate of orthopedic and sports medicine surgeries.

  • In layman’s terms, that means company has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.

Now the firm has appointed Patrick O’Donnell to its board of directors.

  • O’Donnell comes with significant company-building experience
  • He will prove crucial in putting this healthcare pioneer on-track for a NASDAQ listing

Claude LeDuc, Ortho’s CEO, breaks down the appointment:

ORTHO REGENERATIVE TECHNOLOGIES $ORTH.ca $ORTIF ADDS PATRICK O’DONNELL TO BOARD OF DIRECTORS

Posted by AGORACOM-AB at 11:40 AM on Thursday, February 25th, 2021
Ortho

Montreal, QC, February 24, 2021 – Ortho Regenerative Technologies Inc. (CSE: ORTH, OTCQB: ORTIF) (“Ortho RTI” or the “Company”), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today the appointment of Patrick O’Donnell to its Board of Directors, effective immediately. 

“We are very pleased to welcome Patrick to the Ortho RTI Board of Directors to help lead a very important transition in the development of our company, as we prepare to start our first U.S. multisite Ortho-R rotator cuff tear repair Phase I/II clinical trial”, said Claude LeDuc, President and Chief Executive Officer of Ortho RTI. “Ortho RTI will greatly benefit from Patrick’s company-building experience as well as his expertise in the development and management of strategic partnerships fund-raising, commercial, clinical, regulatory and reimbursement strategies, all specific to our industry. We are looking forward to his insightful contribution to our Board”. 

Commenting on his appointment to Ortho RTI’s Board of Directors, Mr. O’Donnell said: “I am happy to be joining the Board of Directors of Ortho RTI. The Company’s proprietary technology platform has the potential to help address significant unmet medical needs in a multitude of soft tissue repair related indications. I am excited to help Ortho RTI develop into an orthobiologics industry leader”. 

Read More: https://agoracom.com/ir/OrthoRegenerativeTechnologies/forums/discussion/topics/755959-ortho-regenerative-technologies-adds-patrick-o-donnell-to-board-of-directors/messages/2305098#message

VIDEO – ORTHO Regenerative Technologies $ORTH.ca $ORTIF is Using Proprietary Tech to Improve Surgery Success Rates and Seize a $5bn Market Opportunity

Posted by AGORACOM-JC at 7:17 PM on Sunday, February 21st, 2021

ORTHO Regenerative Technologies is a cutting-edge med tech firm that uses its proprietary RESTORE technology platform to dramatically improve the success rate of orthopedic and sports medicine surgeries.

  • In layman’s terms, that means company has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.

The technology uses biologics derived from things like plasma and bone marrow concentrate to regenerate new tissue in various musculoskeletal conditions.

  • This includes Wound Healing, Cartilage repair and Osteo-arthritis

So, how big is the market opportunity for Soft Tissue Repair? At least $5bn in the U.S. alone. This includes:

Rotator Cuff TEAR (which leads to shoulder dysfunction and pain):

  • 4m patients in the U.S. alone
  • 600,000 annual surgeries in the U.S. alone
  • $600m+ market opportunity

Meniscus Tear Repair (which is painful and compromises knee function):

  • There are 1.2m surgeries annually in U.S. alone
  • $1bn+ market opportunity

Cartilage Lesions Repair (this is where lesions cause friction and pain):

  • 1.2m detected lesions annually in U.S. alone
  • 120,000 surgeries and a lack of options
  • $1bn+ market opportunity

Get comfy for this insightful interview with Claude LeDuc, Ortho’s CEO.